EQ101
- Generic Name
- EQ101
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Equillium
- Target Recruit Count
- 36
- Registration Number
- NCT05589610
- Locations
- 🇦🇺
Premier Specialists, Kogarah, Australia
🇦🇺Sinclair Dermatology, East Melbourne, Australia
🇦🇺Fremantle Dermatology, Fremantle, Australia
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Equillium
- Registration Number
- NCT03532958
A Multiple-Dose Study of Intravenous BNZ132-1-40 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Bioniz Therapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT03239379
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Bioniz Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT03239392
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸The James Cancer Center, Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath